Decompensated Cirrhosis Clinical Trial
Official title:
Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial
The aim of this study is to evaluate the effect of Entecavir for patients With decompensated HBV-Related cirrhosis.
Chronic hepatitis B is one of the most widespread viral infections worldwide, potentially
leading to liver cirrhosis and hepatocellular carcinoma. Previous studies demonstrated that
patients with active viral replication, defined as the presence of detectable serum HBV-DNA
or HBeAg, were at increased risk of developing progressive liver disease or death.The
prognosis of decompensated cirrhosis resulting from chronic hepatitis B virus infection is
poor. Anti-viral therapy in decompensated HBV-related cirrhosis has been recommended by the
American Association for the Study of Liver Diseases. However, no high quality research on
the effectiveness of anti-viral therapy in decompensated cirrhosis has been performed.
Entecavir is a new nucleotide analogue, which has been proved effective in suppressing viral
replication and decreasing the necroinflammatory response, was recommended as a first-line
medication in AASLD guideline. Our purpose was to evaluate the effect of Entecavir for
patients With decompensated HBV-Related cirrhosis. The main outcomes were liver function,
HBV-DNA, disease progression, hepatocellular carcinoma, Child-Pugh score and the survival.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01701687 -
Biomarkers for the Prognosis of Decompensated Alcoholic Liver Disease
|
N/A | |
| Recruiting |
NCT05121870 -
Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis
|
Phase 2 | |
| Recruiting |
NCT05421351 -
Immune Profile, Neuronal Dysfunction, Metabolomics and Ammonia in Therapeutic Response of HE in ACLF
|
||
| Not yet recruiting |
NCT05086536 -
Re-compensation and Its Clinical Characteristics in HBV Decompensated Cirrhosis
|
||
| Recruiting |
NCT03820271 -
New Prognostic Predictive Models of Mortality of Decompensated Cirrhotic Patients Waiting for Liver Transplantation
|
N/A | |
| Recruiting |
NCT06134544 -
Effect of IMO on Intestinal Microbiota Translocation in Cirrhosis
|
N/A | |
| Recruiting |
NCT06223893 -
CirrhoCare- Using Smart-phone Technology to Enhance Care and Access to Treatment for Cirrhosis
|
N/A | |
| Completed |
NCT02219477 -
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis
|
Phase 3 | |
| Recruiting |
NCT05734001 -
Rotational Thromboelastometry Versus Conventional Haemostatic Tests in Children With Decompensated Cirrhosis Undergoing Invasive Procedures.
|
N/A | |
| Terminated |
NCT04775329 -
Primary Prophylaxis for Spontaneous Bacterial Peritonitis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04422223 -
Prospective Cohort Study of Disease and Outcomes in Cirrhosis
|
||
| Recruiting |
NCT02786017 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs Transplantation for Patients With Decompensated Cirrhosis
|
Phase 1/Phase 2 | |
| Completed |
NCT01326949 -
Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis
|
N/A | |
| Recruiting |
NCT06396897 -
Hospital @ Home Model of Care for Cirrhosis
|
||
| Not yet recruiting |
NCT06306781 -
A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HCL001 Cell Injection (Homologous Allogeneic Hepatocytes) in Patients With Decompensated Cirrhosis
|
N/A | |
| Recruiting |
NCT05227846 -
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1)
|
Phase 1 | |
| Not yet recruiting |
NCT05937048 -
Coagulation Parameters With Albumin in Decompensated Cirrhosis (CoPA-D).
|
N/A | |
| Active, not recruiting |
NCT03205345 -
Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis
|
Phase 2 | |
| Terminated |
NCT03462576 -
Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17
|
||
| Not yet recruiting |
NCT05224960 -
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2)
|
Phase 2 |